166
http://www.DGS-PraxisLeitlinien.deNr.
Nachweis
184
Mercadanti S, Arcuri E. Breakthrough pain in cancer patients: pathophysiology and
treatment. Cancer Treatment Reviews 1998; 24: 425-432.
185
Miguel R. Interventional treatment of cancer pain: the fourth step in the World Health
Organization analgesic ladder? Cancer Control 2000; 7: 149-156.
186
Müller-Schwefe GHH (Hrsg.). Schnellwirksames Fentanyl in der Therapie von Durch-
bruchschmerzen onkologischer Patienten. Thieme Praxis Report 2011; 3(5): 1-16.
187
Mystakidou K, Katsouda E, Parpa E, Tsiatas ML, Vlahos L. Oral transmucosal fentanyl cit-
rate for the treatment of breakthrough pain in cancer patients: an overview of its phar-
macological and clinical characteristics. Am J Hosp Palliat Care 2005; 22(3): 228-232.
188
Mystakidou K, Panagiotou I, Gouliamos A. Fentanyl nasal spray for the treatment of
cancer pain. Expert Opin Pharmacother 2011; 12(10): 1653-1659.
189
Nalamachu S, Hassman D, Wallace MS, Dumble S, Derrick R, Howell J. Long-term
effectiveness and tolerability of sublingual fentanyl orally disintegrating tablet for the
treatment of breakthrough cancer pain. Curr Med Res Opin 2011; 27(3): 519-530.
190
Nalamachu SR, Rauck RL, Wallace MS, Hassman D, Howell J. Successful dose finding
with sublingual fentanyl tablet: combined results from 2 open-label titration studies.
Pain Pract 2012; 12(6): 449-456.
191
National Cancer Institute. Comprehensive Cancer Information.
http://www.nci.nih.gov/cancertopics/pdq/supportivecare/pain/healthprofessional (aufgerufen am 31.10.2025).
192
Nauck F, Eulitz N. Cancer pain management. Basic therapy and treatment of breakt-
hrough pain. Schmerz 2007; 21(4): 359-370.
193
Nauck F, Ostgathe C, Klaschik E, Bausewein C, Fuchs M, Lindena G, Neuwöhner K,
Schulenberg D, Radbruch L; Working Group on the Core Documentation for Palliative
Care Units in Germany. Drugs in palliative care: results from a representative survey in
Germany. Palliat Med 2004; 18(2): 100-107.
194
Nave R, Connolly SM, Popper L, Lahu G, Schmitt H. Single-dose and multi-dose delivery
systems for intranasal fentanyl spray are bioequivalent as demonstrated in a replicate
pharmacokinetic study. Int J Clin Pharmacol Ther. 2012; 50(10): 751-759.
195
Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics of intranasal
fentanyl spray (INFS) in subjects with common cold. Eur J Pain 2009a; 13 (Suppl. 1):
S207.
196
Nave R, Sides EH, Colberg T, Meng X, Lahu G, Schmitt H. Pharmacokinetics of intranasal
fentanyl spray (INFS) in subjects with seasonal allergic rhinitis with and without prior
administration of oxymetazoline. Eur J Pain 2009b; 13 (Suppl 1): S207.
197
Nicholson B, Agarwala SS. Opioid delivery in the treatment of cancer breakthrough
pain: a review of routes of administration. J Opioid Manag 2011; 7(1): 69-79.
198
Núñez-Olarte JM, Alvarez-Jiménez P. Emerging opioid abuse in terminal cancer patients
taking oral transmucosal fentanyl citrate for breakthrough pain. J Pain Symptom Mana-
ge 2011; 42(6): e6-8.
Literaturverzeichnis